Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Ovarian Cancer
Clinical Characteristics of Ovarian Cancer Relapse in BRCA1/2 Germ-Line Mutation Carriers and Noncarriers
ESMO 2018
,
Ovarian Cancer
,
ESMO
Conference Correspondent
Analysis of high-grade serous ovarian cancers suggests that
BRCA1/2
-driven cancers have a more favorable mode of relapse than sporadic cancers.
Read Article
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
,
Ovarian Cancer
2018 Third Annual Oncology Guide to New FDA Approvals
In ovarian epithelial cancer, fallopian tube cancer, and primary peritoneal cancer, malignant cells form in the tissue covering the ovary or lining the fallopian tube or peritoneum. According to the American Cancer Society, in 2017 more than 22,000 women in the United States were estimated to be diagnosed with these cancers and more than 14,000 to die from them.
Read Article
Niraparib Extends Progression-Free Survival in Platinum-Sensitive Ovarian Cancer
By
Phoebe Starr
Ovarian Cancer
November 2016, Vol 7, No 10
Copenhagen, Denmark—Maintenance therapy with niraparib, an oral PARP inhibitor, significantly prolonged progression-free survival (PFS) in patients with recurrent, platinum-sensitive ovarian cancer regardless of their
BRCA
mutation status and homologous recombination deficiency (HRD) status.
Read Article
Veliparib, a PARP Inhibitor, Active in Recurrent BRCA-Positive Ovarian Cancer
By
Charles Bankhead
Ovarian Cancer
June 2014, Vol 5, No 5
Tampa, FL—The poly (ADP-ribose) polymerase (PARP) inhibitor veliparib demonstrated activity in relapsed and/or refractory BRCA-mutated ovarian cancer, according to the results of a phase 2 clinical trial reported at the 2014 Society of Gynecologic Oncology meeting.
Read Article
Oral VEGF Inhibitor, Cediranib, Improves Survival in Recurrent Ovarian Cancer
By
Charles Bankhead
Ovarian Cancer
November 2013, Vol 4, No 9
Treatment with the oral angiogenesis inhibitor cediranib led to significant improvements in overall survival (OS) and progression-free survival (PFS) in patients with recurrent ovarian cancer, according to new data reported at the European Cancer Congress 2013.
Read Article
Deviation from Clinical Guidelines Takes Toll on Ovarian Cancer Survival
By
Charles Bankhead
Ovarian Cancer
,
Personalized Medicine
,
Solid Tumors
May 2013, Vol 4, No 4
Most women with ovarian cancer receive substandard care that significantly reduces their survival odds, based on a new retrospective review of 13,000 patients that was presented at the 2013 Society of Gynecologic Oncology annual meeting.
Read Article
Novel Immunotherapy Approach Encouraging in Advanced Ovarian Cancer
By
Phoebe Starr
Ovarian Cancer
,
Solid Tumors
May 2013, Vol 4, No 4
Washington, DC—A 2-step immunotherapy approach holds promise for women with advanced recurrent ovarian cancer, a disease that has limited therapeutic options.
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma